Influenza Immunization Certification Program and Application  

  •  

    DEPARTMENT OF HEALTH

    Board of Pharmacy

    RULE NO.:RULE TITLE:

    64B16-26.1031Influenza Immunization Certification Program and Application

    NOTICE OF CHANGE

    Notice is hereby given that the following changes have been made to the proposed rule in accordance with subparagraph 120.54(3)(d)1., F.S., published in Vol. 38, No. 96, December 21, 2012 issue of the Florida Administrative Register.

    The change is in response to written comments submitted by the staff of the Joint Administrative Procedures Committee. The changes are as follows:

    1. The following changes were made to form DH-MQA 1234, “Vaccine Immunization Certification Program Application,” effective 01/13:

    On page two, Section I, Number 2, the request for completion of the application for registration as Educational Program Administrator in Florida Pharmacy C.E., has been removed.

    On page three, Section II, Number 5 has been renumbered as 6.

    On page four, Section IV, Number 3, the grammatical error has been corrected.

    2. Subsection (2)(m) shall now read as follows:

    (m) The current influenza, pneumococcal and shingles vaccine guidelines and recommendations of the United States Department of Health Centers for Disease Control and Prevention, which are entitled “Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) – United States, 2012-13 Influenza Season,” dated August 17, 2012; “Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23),” dated September 3, 2010; “Prevention of Pneumococcal Disease Among Infants and Children – Use of 13-Valent Pneumococcal Conjugate Vaccine and 23 –Valent Pneumococcal Polysaccharide Vaccine,” dated December 10, 2010; “Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” dated June 6, 2008; which are hereby incorporated by reference and published at http://www.cdc.gov/vaccines/pubs/ACIP-list.htm;

    THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Mark Whitten, Executive Director, Board of Pharmacy, 4052 Bald Cypress Way, Bin #C04, Tallahassee, Florida 32399-3254.